Search
NewAmsterdam Pharma Company NV
NAMSAdd to Watchlist
33.890USD
+0.020+0.06%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.96BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.06%
5 Days
+7.93%
1 Month
+0.62%
6 Months
-3.39%
Year to Date
-3.39%
1 Year
+87.13%
Key Figures
34.590Open
34.725High
1.08MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.92%Turnover Ratio
33.870Prev. Close
33.575Low
27.88MTurnover
LossP/E Static
5.94P/B
0.00%Div Yield TTM
-27.43%ROA
42.00052wk High
0.79Volume Ratio
-241.60MNet Profit
116.64MShares
-1.7787EPS TTM
0.16Beta
-29.49%ROE
14.06052wk Low
3.40%Amplitude
100.00%Gross Margin
3.96BMarket Cap
1.89Reward/Risk
3.46%Risk Rate
TradingKey Stock Score of NewAmsterdam Pharma Company NV
Currency: USD Updated: 2026-06-30Key Insights
NewAmsterdam Pharma Company NV's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NewAmsterdam Pharma Company NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
NewAmsterdam Pharma Company NV Highlights
StrengthsRisks
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 59.71% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 22.50M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 22.50M.
Undervalued
The company’s latest PE is -19.05, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 128.70M shares, increasing 1.86% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.69M shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
51.500
Target Price
+52.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NewAmsterdam Pharma Company NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NewAmsterdam Pharma Company NV Info
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Ticker SymbolNAMS
CompanyNewAmsterdam Pharma Company NV
CEODavidson (Michael Harvey)
Websitehttps://ir.newamsterdampharma.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52104.000
-92.300 (-0.18%)
30074.100
-150.500 (-0.50%)
7459.700
-22.700 (-0.30%)
15294.000
-301.000 (-1.93%)
70411.000
-445.000 (-0.63%)
6299.000
-28.000 (-0.44%)
69.308
-0.613 (-0.88%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
3967.630
-39.650 (-0.99%)
FAQs
What is the current price of NewAmsterdam Pharma Company NV (NAMS)?
The current price of NewAmsterdam Pharma Company NV (NAMS) is 33.89.
What is the symbol of NewAmsterdam Pharma Company NV?
The ticker symbol of NewAmsterdam Pharma Company NV is NAMS.
What is the 52-week high of NewAmsterdam Pharma Company NV?
The 52-week high of NewAmsterdam Pharma Company NV is 42.00.
What is the 52-week low of NewAmsterdam Pharma Company NV?
The 52-week low of NewAmsterdam Pharma Company NV is 14.06.
What is the market capitalization of NewAmsterdam Pharma Company NV?
The market capitalization of NewAmsterdam Pharma Company NV is 3.95B.
Is NewAmsterdam Pharma Company NV (NAMS) currently rated as Buy, Hold, or Sell?
According to analysts, NewAmsterdam Pharma Company NV (NAMS) has an overall rating of Buy, with a price target of 51.50.
What is the Earnings Per Share (EPS TTM) of NewAmsterdam Pharma Company NV (NAMS)?
The Earnings Per Share (EPS TTM) of NewAmsterdam Pharma Company NV (NAMS) is -1.72.
